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Biomarkers have been examined in schizophrenia research for decades. Medical mor-
bidity and mortality rates, as well as personal and societal costs, are associated with
schizophrenia patients. The identification of biomarkers and alleles, which often have a
small effect individually, may help to develop new diagnostic tests for early identification
and treatment. Currently, there is not a commonly accepted statistical approach to identify
predictive biomarkers from high dimensional data. We used space decomposition-
gradient-regression (DGR) method to select biomarkers, which are associated with the
risk of schizophrenia. Then, we used the gradient scores, generated from the selected
biomarkers, as the prediction factor in regression to estimate their effects. We also used
an alternative approach, classification and regression tree, to compare the biomarker
selected by DGR and found about 70% of the selected biomarkers were the same.
However, the advantage of DGR is that it can evaluate individual effects for each
biomarker from their combined effect. In DGR analysis of serum specimens of US military
service members with a diagnosis of schizophrenia from 1992 to 2005 and their controls,
Alpha-1-Antitrypsin (AAT), Interleukin-6 receptor (IL-6r) and connective tissue growth
factor were selected to identify schizophrenia for males; and AAT, Apolipoprotein B and
Sortilin were selected for females. If these findings from military subjects are replicated
by other studies, they suggest the possibility of a novel biomarker panel as an adjunct to
earlier diagnosis and initiation of treatment.
Keywords: schizophrenia, biomarker identification, space decomposition, gradient, high dimensional data
Introduction
The development of objective tools facilitating identification of subjects at high risk or in a pro-
dromal stage of schizophrenia could enable early interventions aimed to prevent disease occurrence
or improve disease course and consequently reduce the healthcare costs. The precise etiology of
schizophrenia remains uncertain and is most likely multifactorial and complex. Although there is
a great body of research elucidating various factors associated with schizophrenia, some of these
results are inconsistent. Thus, schizophrenia etiology is highly unlikely to be limited to a single risk
factor whether genetic, epigenetic, or environmental. The pathogenesis of schizophrenia involves
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dysfunction of immune, endocrine, and central nervous systems
andmultiple corresponding qualitative and quantitative biochem-
ical alterations (1). Some of these changes could be measured
in sera and used to identify individuals with prodromal disease.
Because serum level variation of a single biochemical molecule
might have a very small effect size, we identified, measured, and
analyzed a combination of 48 potential biomarkers.
The complexity of the task is compounded by the heterogeneity
of schizophrenia reflected in a broad variety of its clinical presen-
tations, some of which could be a result of different etiopathogenic
pathways (2). Studies to determine themost common biochemical
variations distinguishing those who will develop schizophrenia
from those whowill not, would be difficult to replicate in different
schizophrenia populations.
Detecting multiple biomarkers with small individual effects
requires large sample sizes, a large number of biomarkers, and
appropriate statistical approaches to ensure that valuable informa-
tion is not lost. Regression of high dimensional data is difficult for
at least two reasons: sample size and collinearity.When the sample
size is small, traditional regression methods that use the sample
covariance, such as the ordinary least squares (OLS) approach,
perform poorly (3). Therefore, using predictive modeling for
multivariate regression with a large number of biomarkers and
other possible explanatory/predictive variables, for the process of
variable selection and dimension reduction is very challenging.
Multicollinearity, a high correlation of two or more predictors in
a multiple regression, may lead to erratic changes in the effects of
individual biomarkers and large SEs of the coefficient estimates
in response to small changes in the model. As a result it makes
the selection of biomarkers difficult, because the estimated effect
of the predictor variables is expected to be biased. A high degree
of multicollinearity also leads to either software failure in matrix
inversion or inaccurate results.
Principal component analysis (PCA) and ridge regression (4)
are commonly used to solve the collinearities in regression. PCA
is also a commonmethod used to reduce the number of predictive
variables. But PCA identifies linear combinations of variables to
summarize the data in the process. It does not use information
of the dependent variable for the construction of these linear
combinations. The first principal component is often not the
linear combination of the input variables that is most significantly
associated with the dependent variable of disease state (5, 6). The
ridge regression has the same difficulty as OLS when the sample
size is small.
Decision tree learning is a method commonly used in data
mining (7), which is a model that predicts the value of a target
variable based on several input variables. The two main types
of analyses are: classification tree analysis and regression tree
analysis. Classification and regression tree (CART) analysis uses
both of the above procedures, first introduced by Breiman et al (8).
In this study, we applied a decomposition-gradient-regression
(DGR) method, which was originally introduced by Li and
Niebuhr in 2012 Joint Statistical Meeting (http://www.amstat.org/
meetings/jsm/2012/onlineprogram/AbstractDetails.cfm?abstract
id=304618), to select biomarkers for identify the risk of
schizophrenia from a high dimensional case-control data set.
The first step in DGR is to separate the correlated biomarkers
into several subspaces; second step is to find gradient and its
orthogonal vectors in each subspace; and finally, to perform
multiple linear regression on the gradients from each subspace is
performed. The biomarkers in each subspace are independent,
and it does not violate the assumptions of regression modeling,
and we can select the biomarkers used in regression without
collinearity effects. We also compare the results of this approach
with the CART method in this study.
Methods
Data
Data for US military service members who received medical
discharges with a diagnosis of schizophrenia from 1992 to 2005
were obtained from the US Army Physical Disability Agency, the
Secretary of theNavyCouncil of ReviewBoards, and theAir Force
Personnel Center/US Air Force Physical Disability Division (9).
Those aged 18 and older who were on active duty at the time of
their schizophrenia diagnosis, and who had at least one serum
sample of 0.5ml or greater in the Department of Defense Serum
Repository (DoDSR) obtained before diagnosis were selected as
potential study cases. Nearly all (99%) study subjects were hos-
pitalized with a psychiatric disorder before their discharge from
military service. The time of schizophrenia onset was estimated
as the earliest date of either the first hospitalization with psychi-
atric disorder International Classification of Disease 9th Revision
(ICD-9-CM) codes (290-319) or the date the medical or physical
evaluation boards was initiated.
Control subjects were selected from the active duty USmilitary
service population who were over the age of 18 and had no inpa-
tient or outpatient mental health diagnoses. All control subjects
were matched to their cases on gender, race, branch of mili-
tary service, date of birth (12months), and military enlistment
(12months).
The medical and demographic data from 1989 to 2006 were
provided in 2007 by the Defense Medical Surveillance System,
Armed Forces Health Surveillance Center (AFHSC), US. Depart-
ment of Defense (DoD), Silver Spring, MD. Serum specimens
from 1988 to 2006 were retrieved in 2007 from the Department
of Defense Serum Repository (DoDSR), AFHSC, US. DoD, Silver
Spring, MD. However, due to budget limitations, only a subset
of all the schizophrenia cases with their matched controls was
selected for serum sample retrieval. Serum specimens were orig-
inally collected every 2 years for HIV screening and stored at
 30°F. At least one, and up to four,matched (90 days) specimens
were selected for each study subject. The time of specimen col-
lection for controls was determined by date of collection of their
matched cases. The 48 potential biomarkers used in this study
are listed in (see Table 1). The subject distribution and sample
distribution are shown in (see Table 2).
Statistical Analysis
Multicollinearity generates biased estimation in multiple linear
regressions. To avoid collinearity, we first separated the corre-
lated biomarkers into different groups, which we called subspaces.
Second, we found the gradient direction which is the normal
vector of a hyperplane in each subspace that best separates the
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TABLE 1 | List of biomarkers for schizophrenia after decomposition by
subspaces of observed collinearity.
Subspace A
Testosterone, Total
Prolactin (PRL)
Interleukin-6 receptor (IL-6r)
Brain-derived neurotrophic factor (BDNF)
Follicle-stimulating hormone (FSH)
Fetuin-A
Apolipoprotein A-I (Apo A-I)
Interleukin-7 (IL-7)
Carcinoembryonic antigen (CEA)
Beta-2-Microglobulin (B2M)
Prostatic acid phosphatase (PAP)
Peptide YY (PYY)
Macrophage migration inhibitory factor (MIF)
Epidermal growth factor receptor (EGFR)
Serum amyloid P-component (SAP)
Vascular endothelial growth factor (VEGF)
Immunoglobulin M (IGM)
TNF-related apoptosis-inducing ligand
Receptor 3 (TRAIL-R3)
Interleukin-10 (IL-10)
Luteinizing hormone (LH)
Matrix Metalloproteinase-2 (MMP-2)
Vitronectin
Endothelin-1 (ET-1)
CD5 (CD5L)
Alpha-1-antitrypsin (AAT)
Apolipoprotein B (Apo B)
Macrophage-derived chemokine (MDC)
Cortisol (Cortisol)
Ferritin (FRTN)
Intercellular adhesion molecule 1 (ICAM-1)
Betacellulin (BTC)
Cancer antigen 125 (CA-125)
Monocyte chemotactic protein 2 (MCP-2)
Subspace B
Apolipoprotein H (Apo H)
Tumor necrosis factor receptor 2 (TNFR2)
Connective tissue growth factor (CTGF)
Sortilin
Kidney Injury Molecule-1 (KIM-1)
Macrophage Inflammatory Protein-1 alpha (MIP-1 alpha)
Serotransferrin (Transferrin)
Thyroid-stimulating hormone (TSH)
Apolipoprotein C-I (Apo C-I)
Haptoglobin
Tissue inhibitor of metalloproteinases 1 (TIMP-1)
Immunoglobulin A (IgA)
Subspace C
Apolipoprotein A-II (Apo A-II)
Complement C3 (C3)
Calbindin
cases and controls within the subspace (10). The gradient score is
the linear combination of the standardized values of biomarkers
used in each subspace. Scores were generated for the gradient and
their perpendicular vectors in each subspace. The gradient score
and the other significant vector scores from each subspace were
used as the factor in statistical modeling. Third, we eliminated
the noneffect biomarkers backwards by examining the coeffi-
cients of the gradient and the effect of gradient score modeling
in each subspace. Then applying the regression model on the
TABLE 2 | Subject and serum specimen frequencies by gender, race, and
age.
Factor Level Schizophrenia subjects Serum specimens
Count % Count %
Gender Female 25 8:5 65 12:2
Male 269 91:5 469 87:8
Race Black 90 30:6 170 31:8
Other 31 10:5 60 11:2
White 173 58:8 304 56:9
Age <25 191 65:0 349 65:4
25 103 35:0 185 34:6
gradient scores of select biomarkers, we evaluated the joint effect
of biomarkers on schizophrenia and the individual effect for
schizophrenia.
Two kinds of data were used to check the effects of the gradient
and the orthogonal vector scores. One is the USmilitary data, and
the other is simulated data, which includes one binary outcome
Y and 100 predictors. In the simulated data, a few predictors
have effect on Y with selected association, while the others have
no effects on Y. The results from both kinds of data showed
that no score other than the gradient score had a significant
effect to distinguish the binary outcome. The gradient score con-
sisted of nearly all the information from all biomarkers in the
gradient.
Given that multiple serum samples were collected for each
subject from different times before diagnosis, the generalized esti-
mating equation was used to estimate the unknown parameters
(11). The odds ratio and 95% confidence interval or p-value was
reported using Bonferroni correction. The degrees of freedom of
the Wald chi-square value of the gradient score was adjusted by
the number of biomarkers used in the gradient vector.
The coefficient of a biomarker in the gradient vector describes
its contribution to distinguish the schizophrenia cases from the
controls. If the coefficient of a given biomarker is near 0, it implies
that it has no effect on schizophrenia, which can then be elimi-
nated from the gradient without loss of information. Hence, we
can eliminate the nonsignificant biomarkers one by one.
Two approaches for the number of biomarkers to be selected
were used. The first approach was decided by the surface of
sensitivity versus the numbers of biomarkers used in subspaces
A and B constructed by regression model for all subspaces with
different dimensions or by biological plausibility arguments from
epidemiologists. The second approach used the Akaike informa-
tion criterion (AIC): AIC= 2p  2Log L, which is a measure of
the quality of fit of a statistical model for a given set of data, where
p is the number of parameters in the regression. For longitudinal
GEE regression, the quasi-likelihood information criterion (QIC),
which uses the quasi-likelihood to replace the likelihood in AIC,
is commonly used (12). When we use the gradient score in the
model, we count the number of parameters in the gradient score
as k rather than 1, where k is the number of biomarkers used in
the gradient score. It can be seen from (see Table 2), the military
data was longitudinal, and hence we minimized the adjusted QIC
for selection of the final predictive biomarkers.
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Results
Biomarker Selection
Among the 48 biomarkers, one pair was highly correlated, with a
Pearson correlation coefficient of 0.87; three pairs had an absolute
value of Pearson correlation coefficient over 0.6, and over 20
pairs of biomarkers, had an absolute value of Pearson correlation
coefficients over 0.40. First, using Pearson correlation coefficient
of0.4 as the threshold, the 48 biomarkers were assigned to three
groups: subspaces A, B, and C. There were three biomarkers in
subspace C; all of them were eliminated because they made no
contribution to identify schizophrenia cases. The effect of gradient
C score was around 0. The gradient scores were highly significant
in both subspaces A and B by using Bonferroni criterion (adjusted
p< 0.05/kA and 0.05/kB, respectively, where kA and kB were the
number of biomarkers used in the gradients in subspacesA andB).
Using the backward selection approach, the biomarker with
the coefficient nearest to 0 in the gradient was eliminated
one by one. The average sensitivity for schizophrenia status
among 100 simulations was used to make the surface graphs
by the number of biomarker used in subspaces A and B (see
Figures 1 and 2). For each simulation, two-thirds of subjects
FIGURE 1 | Average sensitivity to predict schizophrenia of training group by number of biomarkers in subspaces A and B.
FIGURE 2 | Average sensitivity to predict schizophrenia of testing group by number of biomarkers in subspaces A and B.
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FIGURE 3 | Quasi-likelihood information criterion in subspace A.
FIGURE 4 | Quasi-likelihood information criterion in subspace B.
were selected randomly in the training dataset to fit the model,
and the remaining one-third of the subjects was in the test-
ing set to verify the model. For the subspace A, the sensitivity
increased with the number of biomarkers until peaks for the
training set (13 biomarkers) and testing set (11 biomarkers) were
reached. Further increases in the number of biomarkers did not
yield any improvement in sensitivity. Selecting four biomarkers
for subspace B was sufficient as no monotonic change in sen-
sitivity was observed when the number was further increased.
The QIC curve by the number of biomarkers in subspace A
is shown in (Figure 3), which was minimized at k= 12. But,
the curve has a jump at five and six biomarkers. For subspace
B in Figure 4, three and four biomarkers were the optimal
selection.
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The Effects of Selected Biomarkers
Next, we used the selected 12 and 6 biomarkers from subspace
A as well as three biomarkers from subspace B to generate the
gradient scores to fit the logistic model with a GEE approach.
We found only minor difference between odds ratios in the two
situations of different number of biomarkers used in the sub-
space A. The OR= 1.77 for increasing one SD of gradient score
using 12 biomarkers, and OR= 1.5 for the gradient increasing
using six more significant biomarkers among the 12; both were
significant. This implies that six additional biomarkers made
minor contributions in distinguishing schizophrenia cases from
controls. The results for six biomarkers in subspace A and three
biomarkers in subspace B are shown in Table 3. The gradient
was the most significant vector among the orthogonal vectors
in subspace A, and the p-value was much smaller than the
critical value by Bonferroni correction (0.0083) for both males
and females. Similarly for the three biomarkers in subspace B,
by adjusting for multiple comparisons (α= 0.0167) the gradient
score was also significant. More conservatively, by using Wald
chi-square approach, the adjusted chi-squared test p-value for
gradient score in subspace A was still highly significant, while
the p-value for gradient score in subspace B only approached
significance (13).
Table 4 lists the standard coefficients of the biomarkers in the
gradient scores. The percentage of contribution on the gradient
score effect on schizophrenia is the square of the coefficients. The
third column is the odds ratio for increasing one unit of the indi-
vidual biomarkers along the gradient direction. Using the SE of
the gradient score, the odds ratios of Alpha-1-antitrypsin (AAT),
Interleukin-6 receptor (IL-6r) and connective tissue growth fac-
tor (CTGF) showed significant effects to identify schizophrenia
for males; AAT, Apolipoprotein B (Apo B) and Sortilin showed
significant effects for females. It was observed that the risks for
increasing gradient score for females were much higher than that
for males.
Table 5 shows biomarkers selected by DGR and CART meth-
ods; about 70% are the same. However, using CART, we cannot
estimate the effect on the outcome by individual biomarkers.
TABLE 3 | The odds ratio for one SD increasing in gradient score.
Gender Gradient score
by subspace
OR ORL ORU Unadjusted
p-value generated
in model
Significance
by Bonferroni
correction
Adjusted Wald
Chi-square
p-valuea
Female A 3:88 2:29 7:03 2.10E–06 Yes 0:001
B 1:82 1:2 2:86 0.00728 Yes 0:063
Male A 1:5 1:27 1:77 2.00E–06 Yes 0:001
B 1:25 1:05 1:5 0.01305 Yes 0:111
Both A 1:79 1:51 2:15 7.87E–11 Yes 0
B 1:19 1:05 1:36 0.006 Yes 0:074
aAdjusted the degrees of freedom based on the number of biomarkers used in the gradient.
TABLE 4 | The risk of schizophrenia for selected biomarkers.
Subspace Male Female
Biomarkers Gradient
score
coefficient
Percentage
contribution
Odds
ratiob
Biomarker Gradient
score
coefficient
Percentage
contribution
Odds
ratiob
A Alpha-1-antitrypsin (AAT) 0:47 0.22 1:21a Alpha-1-antitrypsin (AAT)  0:58 0.34 0:45a
Apolipoprotein A-I
(Apo A-I)
0:38 0.14 1:16 Apolipoprotein B (Apo B) 0:48 0.23 1:92a
Immunoglobulin M (IGM)  0:33 0.11 0:87 Cortisol (Cortisol)  0:30 0.09 0:66
Interleukin-6 receptor
(IL-6r)
 0:53 0.28 0:81a Endothelin-1 (ET-1)  0:33 0.11 0:64
Prolactin (PRL) 0:36 0.13 1:16 Fetuin-A 0:36 0.13 1:62
Serum amyloid
P-component (SAP)
0:35 0.12 1:15 Interleukin-10 (IL-10) 0:32 0.10 1:54
B Apolipoprotein H (Apo H)  0:65 0.19 0:94 Haptoglobin 0:42 0.18 1:29
Immunoglobulin A (IgA) 0:51 0.26 1:12 Sortilin  0:73 0.54 0:64a
Connective tissue growth
factor (CTGF)
0:56 0.54 1:24a Macrophage inflammatory
protein-1 alpha (MIP-1
alpha)
 0:53 0.34 0:68
aSignificant at level <0.05.
bFor one increasing SD.
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TABLE 5 | List of biomarkers for schizophrenia selected by subspace using
decomposition-gradient-regression method (DGR) versus classification
and regression tree (CART).
Subspace Biomarkers
DGR CART
A Alpha-1-antitrypsin (AAT)a Alpha-1-antitrypsin (AAT)a
Apolipoprotein A-I (Apo A-I)a Brain-derived neurotrophic
factor (BDNF)
Epidermal growth factor
receptor (EGFR)
Cancer antigen 125 (Ca-125)
Ferritin (FRTN) Carcinoembryonic antigen
(Cea)
Fetuin-A Connective tissue growth factor
(CTGF)a
Immunoglobulin M (IGM)a Cortisol (Cortisol)
Interleukin-6 receptor (IL-6r)a Interleukin-6 Receptor (IL-6r)a
Macrophage migration
inhibitory factor (MIF)a
Prostatic acid phosphatase
(Pap)
Peptide YY (PYY) Sortilina
Prolactin (PRL)a Macrophage migration
inhibitory factor (Mif) a
Serum amyloid P-Component
(SAP)
Haptoglobina
B Apolipoprotein H (Apo H) Immunoglobulin A (IgA)a
Connective tissue growth factor
(CTGF)a
Immunoglobulin M (IGM)a
Haptoglobina Prolactin (PRL)a
Immunoglobulin A (IgA)a Thyroid-stimulating hormone
(Tsh)
Macrophage inflammatory
protein-1 alpha (MIP-1 alpha)
Vitronectin
Sortilina Apolipoprotein A-I (Apo A-I)a
aBiomarkers are associated with decreased risk of schizophrenia by both DGR and CART.
Individual Effect of Biomarkers on Schizophrenia
AAT was selected for both males and females by DGR, and had
nearly the highest absolute effect for both genders, but was a risk
factor for males and a protective factor for females. Similar results
have been reported elsewhere (14). The signs and symptoms of
schizophrenia and the age at which they appear, vary among indi-
viduals. In our data, themean and SDofAAT for femaleswere 21.1
(37.8) for cases, and 12.2 (17.3) for controls; for males, 7.8 (7.3)
for cases and 6.5 (4.4) for controls. This explained the variation of
the AAT effect by gender. Rudduck et al. studied the AAT effect
on schizophrenia and claimed that significant differences with
respect to phenotype (p< 0.05) and gene (p< 0.025) frequencies
were found between the two groups of patients (15).
Interleukin contributed the highest risk (28%) in the gradient
for males, as deficiency of one unit along the gradient direction
increased the risk of schizophrenia by about 25% (OR= 0.81).Our
findings were consistent with a recent study by Hope et al. (16).
The CTGF also showed a significant effect on schizophrenia
status for males, with the highest contribution (54%) on the
gradient score in subspace B. CTGFwas identified to be associated
with schizophrenia syndrome (17). Apo B was found to be a
significant biomarker for risk of violent behavior (18).
The gradient score risk in subspace A for females was almost
fourfold; the highest contribution was from AAT (34%), while
Apo-B had the second highest contribution (24%). In prior
studies, AAT was found to be correlated with violent behavior
(19). Sortilin had the highest contribution (54%) on the gradient
score for females in subspace B. However it was protective, with
an OR of 0.64. Decreasing Sortilin would increase the risk of
schizophrenia. We did not find literature on Sortilin’s effect on
schizophrenia, however Chen et al., concluded that Sortilin was
associated with BDNF (20). Similar to our findings, Reichelta and
Landmark had found that IgA antibody increased schizophrenia
risk (21). Apolipoprotein A-I (Apo A-I) was another risk factor
of schizophrenia for males. An increase of one unit of Apo A-
I in the gradient direction resulted in a nearly 16% increase in
the risk of schizophrenia. It contributed 14% of the risk in the
gradient. A recent study by Song et al. (22) suggested that APO
A-I might be a novel biomarker related to metabolic side effects in
first episode schizophrenia treated with risperidone (22). Another
selected biomarker was prolactin, which contributed 13% of the
risk and an odds ratio of 1.16, but not significant. This finding
is consistent with Song et al. (23) finding that the schizophrenia
group had higher serum levels of PRL, IL-1β, IL-6, and TNF-α
compared with the control group (23). Wang et al. also concluded
prolactin had an effect on schizophrenia status (24).
Discussion
In this study, we validated a novel, three step biomarker selection
processes to identify schizophrenia cases based on biological and
technical reproducibility of the molecular signature. The first step
involved decomposition of the sample space by examining the
dependency of 48 biomarkers separated into three subspaces to
avoid collinearity. The second step involved biomarker selection
using the gradient in each subspace to use a few parameters in
the regression without losing information and to select important
biomarkers. Step three identified the effects of biomarkers’ in
combination and individually. Comparable results were found by
DGR andCART. The advantage of DGR is that themagnitude and
direction of the biomarker effects can be estimated. The meaning
of the association expressed as an odds ratio is also clearer and
more easily explained in DGR.
We have used a novel approach to identify the potential
biomarkers for diagnosis of schizophrenia. The reliable identifica-
tion of biomarkers with predictive power among the high dimen-
sional data is a key discipline in modern pharmaceutical and
biotechnical research. Once these biomarkers have been found, we
can use them to identify patients earlier and distinguish diseased
from normal subjects. Selecting a few predictive biomarkers has
a number of advantages in both epidemiology and statistical
analyses: (1) the risk of over fitting is reduced which improves
the predictive accuracy; (2) the number of parameters is reduced
which decreases the sample collection costs; and (3) models based
on fewer factors are often easier to interpret. The ideal biomarker
selection method should achieve two objectives: eliminate trivial
variables, and include whole groups of correlated predictors into
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the model, to identify biomarkers with strong joint effects (25).
The DGR approach first separates the whole space into several
subspaces. The correlated biomarkers with similar effects on pre-
diction are separated into different subspaces; if one is selected in a
subspace, usually the others will be selected in different subspaces.
Due to multicollinearity, without decomposition, some or all will
not be eliminated in the multiple regression. By using AIC/QIC
or sensitivity analysis, we can decide the number of biomarkers
to be selected: explainable with fewer predictors. We can set the
statistical analytic program to select biomarkers automatically.
From the military data and the 48 biomarkers, AAT,
Interleukin-6 receptor (IL-6r), and CTGF show significant effects
to identify schizophrenia status inmales; AAT, Apo B, and Sortilin
show significant effects in females.
However, due to variations in serum specimens and the
biomarker assays, some biomarkers might be selected by chance;
the final selected biomarkers will likely vary from study to study.
Ideally, the biological mechanisms of the biomarkers should be
considered to avoid selection bias in the final predictive model. If
these findings are replicated by other studies or data from other
populations, they suggest the possibility of a novel biomarker
panel as an adjunct to earlier diagnosis and initiation of treatment.
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